AMB-FUBINACA

AMB-FUBINACA

AMB-FUBINACA is a synthetic cannabinoid that has been identified in illegal herbal products. AMB-FUBINACA was originally developed by Pfizer in 2009 as an analgesic medication, but it was not pursued for human use. Later, it emerged on the designer drug market, where it has been found in products marketed as herbal incense or "spice."

Chemistry

AMB-FUBINACA is a member of the indazole family of cannabinoids, specifically an indazole-3-carboxamide. Its chemical name is N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide. The compound features a fluorobenzyl group attached to the indazole core, as well as a terminal amide group derived from tert-butylamine.

Pharmacology

As with other synthetic cannabinoids, AMB-FUBINACA acts as a potent agonist for the cannabinoid receptors CB1 and CB2, with a particular affinity for the CB1 receptor, which is predominantly found in the central nervous system. The activation of these receptors is responsible for the psychoactive effects associated with its use. However, the exact pharmacological profile of AMB-FUBINACA and its full spectrum of effects are not well understood, due to the lack of comprehensive studies.

Effects

Users of AMB-FUBINACA have reported effects similar to those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. These effects include euphoria, relaxation, altered perception, and, in some cases, anxiety and paranoia. However, due to its potency, the risk of experiencing adverse effects, including severe toxicity and life-threatening conditions, is significantly higher than with natural cannabis.

Legal Status

The legal status of AMB-FUBINACA varies by country and jurisdiction. It has been listed as a controlled substance in several countries due to concerns about its potential for abuse, addiction, and health risks. In the United States, AMB-FUBINACA is classified as a Schedule I controlled substance, making its manufacture, distribution, and possession illegal.

Health Risks

The use of AMB-FUBINACA has been associated with serious health risks, including acute intoxication, organ damage, and death. Cases of severe intoxication have resulted in hospitalizations, with symptoms such as tachycardia, hypertension, nausea, vomiting, agitation, seizures, and unconsciousness. The lack of research and understanding of this compound increases the risk associated with its use, as the full range of its toxicological profile and interactions with other substances is unknown.

Conclusion

AMB-FUBINACA is a synthetic cannabinoid with significant health risks and legal implications. Its emergence on the designer drug market highlights the ongoing challenge of addressing the use of novel psychoactive substances. Public health efforts should focus on education, prevention, and the development of strategies to identify and mitigate the risks associated with synthetic cannabinoids.

This article is a stub. You can help WikiMD by registering to expand it. Editing is available only to registered and verified users. WikiMD is a comprehensive, free health & wellness encyclopedia.